ReACT Therapeutics’ Post

We're honored to welcome NeuroSense Therapeutics to participate in the upcoming B2i Digital Featured Conference: Spartan Capital Securities, LLC Investor Conference 2024. The event is scheduled for November 4th at The Pierre Hotel in New York City. NeuroSense Therapeutics, Ltd. (Nasdaq:NRSN) is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases. NeuroSense Therapeutics's leadership team includes Alon Ben-Noon 🇮🇱, Ferenc Tracik, MD, Niva Russek- Blum, Hagit Binder, Or Eisenberg, Sharon Cohen-Vered, Diana S., Shiran Zimri, Yael Barak, Nedira Salzman-Frenkel, Dorit Jacob, Vered Sasson 🇮🇱, Eidan Loushi, Nitai Kerem, Keren Pushett and many other talented individuals including Natalya Rudman at crescendo-ir.com. Conference attendees will be uniquely able to engage directly with executives, gaining valuable insights into the company’s developments. The Spartan Capital Investor Conference brings together an impressive array of public company executives, institutional investors, and thought leaders in the U.S. capital markets. With over 30 companies slated to present, the event promises unparalleled networking opportunities. For those interested in attending this exclusive event, please submit a request to participate at https://lnkd.in/e6ZQhZyA Kindly note that attendance is limited and subject to approval. Thank you to our hosts at Spartan Capital: John D. Lowry, Kim Monchik, Joe Giamichael, Stephen Faucetta, Julia Voss, William Birney, Donald Powell, Louis Valdez, Abdiell (AJ) Suero, Blake Weltmann, Ralph Metz and many others. #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024

#Mirxes’s collaboration with A*STAR - Agency for Science, Technology and Research rested on three main pillars: first, the development of novel technologies; second, a symbiotic exchange of talent; and third, the brand recognition of having A*STAR as a partner. Our close association with A*STAR is a signal to our investors, customers and partners that Mirxes is trusted partner that delivers quality. Mirxes spun off from A*STAR in 2014, and we are grateful for further collaboration opportunities from working with A*STAR’s research institutes on GASTROClear, the Fortitude Kit, COVID-19 PCR diagnostic test kit, to opening our Mirxes - A*STAR Joint Lab this year. We look forward to continuously co-developing and delivering world-class medtech solutions, and ushering in the era of precision medicine together. Read the full article: https://lnkd.in/grcbms5R #preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetection #earlydetectionsaveslives #healthcare #cancerearlydetection #RNA #research #earlydetection #cancer #cancerresearch

With its stunning landscapes and renowned culinary delights, Switzerland is a country that captivates visitors. Beyond its natural beauty and delicious delicacies, Switzerland boasts a robust biotech industry with a focus on groundbreaking innovations. The Swiss biotech sector is at the forefront of developing new cancer treatments and immunotherapies, with industry giants like Novartis and Roche leading the way. Additionally, Switzerland serves as a prominent hub for gene and cell therapy advancements, including research on combating aging and age-related diseases. Not just a picturesque destination, Switzerland's biotech landscape showcases a commitment to pioneering healthcare solutions, with companies like Rejuveron Life Sciences making significant strides in this critical field. Explore the dynamic intersection of science and innovation in Switzerland's biotech industry. #Switzerland #Biotech #Innovation

🚀 Exciting news! Diana Caldwell of Amplified Sciences, Inc., a cutting-edge clinical-stage life science diagnostics company, is attending RESI Boston as an #NIH NIH SEED sponsored company! 🎉 Investors, don't miss this opportunity to connect with a company that's transforming early disease detection. 🔬 Amplified Sciences is leveraging an ultra-sensitive molecular-sensing platform technology, exclusively licensed from Purdue University, to accurately detect debilitating diseases at earlier stages. Their lead assay, PanCystPro™️, is a game-changer in the early detection of pancreatic cancer. 🎯 With a remarkable +95% Negative Predictive Value (NPV), PanCystPro™️ is highly effective at ruling out potential malignancy in high-risk pancreatic cystic lesion patients. What sets it apart is its ability to operate with 50x less fluid volume than competitors, enabling earlier detection and better risk stratification for patients at risk for pancreatic cancer. 💡 Amplified Sciences' innovative approach promises to make a significant impact on how we identify and manage pancreatic cancer, offering hope for earlier intervention and improved patient outcomes. 💥 If you’re an investor looking for a breakthrough in life science diagnostics, connect with Amplified Sciences at RESI Boston and discover how they're leading the way in early disease detection. 💰💼 #HealthcareInnovation #Diagnostics #LifeSciences #PancreaticCancer #InvestInInnovation #RESIBoston #InVitroDiagnostics #EarlyDetection Anna Zornosa Brittany Connors, PMP Xing-Jian Lou Ethel Rubin

🔥Peter Lebowitz , 🚀Third Arc Bio 🚀🌟ThirdArc Bio Launches with Oversubscribed $165 Million Series A Financing to Deliver Superior Biologics for Solid Tumors and Inflammatory & Immunology (I&I) Diseases🚀🌟 🔥Pioneering Innovation: Third Arc Bio’s focus on delivering superior biologics for solid tumors and inflammatory & immunology (I&I) diseases highlights the importance of pushing the boundaries of innovation in the medical field. 🔥Securing Strong Support: Raising $165 million in an oversubscribed Series A financing round demonstrates the power of a compelling vision and strong market need, attracting substantial investor support. 🔥Addressing Critical Needs: Focusing on critical health issues like cancer and I&I diseases showcases a commitment to making a significant impact on global health, emphasizing the value of working on projects that address pressing societal needs. 🔥Strategic Fundraising: The success of Third Arc Bio’s fundraising effort underscores the importance of strategic planning and effective communication with potential investors. 🔥Collaborative Efforts: Such a large financing round often involves multiple investors, highlighting the importance of building strong relationships and collaborating with various stakeholders to achieve common goals. 🔥Commitment to Excellence: The company’s focus on superior biologics reflects a commitment to excellence and continuous improvement in their field, inspiring others to strive for the highest standards. 🔥Market Confidence: Oversubscribed funding rounds indicate high confidence from the market in the company’s potential, reinforcing the importance of building trust and credibility. 🔥Cutting-Edge Research: Third Arc Bio’s work is at the cutting edge of biomedical research, showcasing the importance of staying at the forefront of scientific advancements. 🔥Long-Term Vision: Raising such a significant amount in Series A funding points to a clear and ambitious long-term vision, essential for sustained growth and impact. 🔥Inspiring Others: Third Arc Bio’s achievement serves as a powerful example of what is possible with dedication, innovation, and strong support, motivating others in the field to pursue their goals passionately. ✅️Share Your Startup Story 🚀📲 https://lnkd.in/ggir3Qap ✅️visite our website🌐 https://lnkd.in/dad4nH #Biotech #Innovation #MedicalResearch #Healthcare #Investment #Fundraising #Biologics #CancerResearch #Immunology #LongTermVision #Inspiration #scoopearth

#Mirxes is honoured and delighted to have Deputy Prime Minister, Coordinating Minister for Economic Policies and Chairman of the National Research Foundation, Mr Heng Swee Keat inaugurate the NUH Diagnostic Molecular Oncology Centre (DMOC) @ Biopolis, Singapore's first public-private partnership centre for specialty molecular testing, yesterday. Dr Lihan Zhou, Co-Founder and CEO of Mirxes shared, “The inauguration of the NUH DMOC@Biopolis is a significant milestone in Singapore's journey towards a future of advanced and accessible precision medicine. This public-private partnership is a landmark achievement, leveraging Mirxes' leading technology and NUH's pathology expertise. Together, we're transforming cancer care for all patients in Singapore and the region through NGS.” The Centre offers the APEX (Actionable, Personalized, EXpress) cancer treatment selection test, a cutting-edge 50-gene targeted Next Generation Sequencing (NGS) panel, which reduces costs by more than 50% for patients, has a faster turnaround time of just eight working days, and provides improved patient access. Too Heng-Phon Wee Joo Chng Soo-Yong Tan Chorh Chuan Tan Photo credit: National University Hospital #preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetection #earlydetectionsaveslives #healthcare #cancerearlydetection #NGS #Genomics #Biotech #NGSSequencing #GenomicsResearch #NextGenSequencing #DNASequencing #GenomeAnalysis

Announcement: Overarching agreement with Dundee University and Initiation of Evaluation project.    We are thrilled to announce the signature of an over-arching agreement with the University of Dundee and their Drug Discovery Unit, University of Dundee (DDU) to access research relating to novel therapeutic candidates.    The first Evaluation Agreement under the framework focuses on investigating a lead series of therapeutic candidates in the increasingly important research area of pro-senescence (selectively promoting ageing of cancer cells to cease growth in tumours). This exciting area of research has the potential to be effective in treating multiple cancer types, and also many other disease areas, including those associated with healthy ageing.    This work builds upon previous ground-breaking research by Dundee and Barts Charity funded research by Prof Cleo Bishop, Professor of Senescence and Director of the Queen Mary University of London Phenotypic Screening Facility.    Speaking about the agreement, ValiRx CEO Dr Suzy Dilly said: "We are delighted to be able to streamline the process of reviewing and accessing the excellent research from the University of Dundee's DDU, which will help to bring on evaluation projects more quickly."    Professor David Gray, Head of Biology and innovative targets portfolio lead at the DDU commented "We are delighted that our UKRI Impact Accelerator Award has enabled us to translate the groundbreaking work of our collaborator Cleo Bishop at Queen Mary University London, to the point where ValiRx see the potential for treating patients."    Watch the announcement video, recorded by BRR Media, where ValiRx CSO Dr Cathy Tralau-Stewart explains the agreement in more detail: https://lnkd.in/gVcwHvPZ   #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch

🔬 BIOGENERA SpA: 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲, 𝗢𝗻𝗲 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗮𝘁 𝗮 𝗧𝗶𝗺𝗲🔬 At Biogenera, we are at the forefront of biotechnological innovation, driven by a bold vision: to develop personalized therapies for diseases that today lack effective treatments. Our pipeline is the roadmap to achieving this vision, reflecting our commitment to transforming cutting-edge research into life-changing solutions. 💡 What sets our pipeline apart? • Focus on Rare Diseases: We concentrate on addressing unmet medical needs, focusing on rare and life-threatening diseases that impact patients and families globally. • Personalized Approach: Our innovative technologies enable us to develop therapies tailored to the genetic and molecular profiles of individual patients. • Preclinical and Clinical Progress: From initial discovery to advanced preclinical and clinical phases, each step is a testament to our rigorous research and determination. 📋 Highlights from Our Pipeline: • BGA002: Our leading candidate, a cutting-edge therapy targeting pediatric cancers, is making significant strides in preclinical studies. • Rare Cancer Therapies: Ongoing programs focus on specific subtypes of leukemia and sarcomas, aiming to provide effective options for diseases that currently lack viable treatments. • Proprietary Technology: Leveraging our unique DNA-drug platform, we’re accelerating the discovery and development of targeted therapies that minimize side effects while maximizing efficacy. 🌟 Why it matters: Our work isn’t just about science; it’s about hope—hope for patients, families, and communities facing the toughest challenges. Each project in our pipeline brings us one step closer to changing lives and making a tangible difference in the field of precision medicine. 🚀 Join Us on This Journey: As we continue to push boundaries in science and innovation, we invite you to be part of our mission. Whether as a partner, an investor, or a supporter, your role is crucial in driving these transformative therapies forward. Together, let’s redefine the future of medicine: https://lnkd.in/dfxS7AJ8 . #Biogenera #Innovation #PrecisionMedicine #DrugDevelopment #Pipeline #Biotech #RareDiseases #PersonalizedTherapies #Research #FutureOfMedicine

#CancerFightingDrug #MonoclonalAntibody #DNADamageRepair #NOV2 #Immunotherapy #CancerCellNuclei #Combination #Fundraising #Partnership #RESIBoston2024 Our #CEO Zakia BELAID-SANDAL and #ScientificBusinessDevelopment #Advisor Bill Kohlbrenner will be partnering at RESI Boston 2024 #RESIBOSTON invited by the CEO of Life Science Nation (LSN) (#Connecting #products, #Services and #Capital) Dennis Ford . Send us a meeting request at https://lnkd.in/gEecZet5 and view the program guide at https://lnkd.in/e7iNwSFW to share the progress we have made in advancing our NOV2 asset, which is a novel biologic with promising potential as an anti-cancer therapeutic. This humanized mAb modulates a novel signaling pathway, uncovered by our company founder, mediated by the leptin-dependent NRP-1 (neuropilin-1)/OBR receptor complex. NOV2 has a unique MOA: upon binding to the target, NOV2 is internalized to the nucleus of cancer cells which stimulates significant DNA damage and telomere shortening. In vivo cancer cell models also reveal that NOV2 stimulates a significant immune response. We believe that NOV2 offers significant potential as a combination agent that can enhance the efficacy of immunotherapies, angiogenesis inhibitors, etc. This asset is patent protected and we have scaled up enough material for advanced biological profiling. We are seeking support to further advance our program. We are open to investment and/or collaboration. The project is #laureate of #ilab2020 iLab #InnovUpPIA2021 #NETVAstartInAmerica2024 competitions Inserm Transfert Ministère de l'Enseignement supérieur et de la Recherche Ministère des Affaires étrangères français Bpifrance Région Ile de France Consulate General of France in Boston Embassy of France in the United States La Synapse France Science

We are pleased to announce that ALZpath Inc. has entered a strategic partnership with Bio-Techne® to advance neurodegenerative disease research! ALZpath's pTau217 antibody will now be incorporated into Bio-Techne's Simple Plex™ assays on the Ella™ platform. This collaboration brings the launch of the Simple Plex Human Phospho-Tau (T217) ALZpath Assay—a tool designed for Alzheimer's disease researchers to achieve accurate, sensitive, and high-precision results. The Ella platform offers researchers decentralized, hands-free immunoassays with results in just 90 minutes, streamlining workflows and enabling rapid insights into biomarkers like pTau217. "As cases of Alzheimer’s disease continue to rise worldwide, this collaboration provides an opportunity to leverage our proprietary pTau217 antibody to advance promising research and development of new treatments,” said Chad Holland, CEO and President of ALZpath. This partnership marks a vital step toward expanding access to advanced diagnostic tools and accelerating the development of new treatments. 📌 Learn more about this exciting partnership in our press release: https://lnkd.in/g9SaGQ3U 📌Visit our website for more details: https://alzpath.bio #ALZpath #BioTechne #NeurodegenerativeDisease #AlzheimersResearch #pTau217